TOPIC 313 PHASE I; RNAI CANCER THERAPEUTICS USING NANOTECHNOLOGY; HHSN2612013000
$200,000N43FY2013CANIH
Genesegues, Inc., Chaska MN
Investigators
Abstract
The design, fabrication, characterization, and preclinical evaluation of novel nanoparticle-based drug formulations capable of delivering candidate RNAi therapeutics for the treatment of cancer.
View original record on NIH RePORTER →